Alzheon IPO take two: Will investors back a downsized offering from an Alzheimer’s biotech?
Alzheon couldn’t manage to pull off an $80 million IPO as a string of biotechs lined up to go public earlier this year. So now …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
